BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27035988)

  • 21. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
    Jain RK; Tong RT; Munn LL
    Cancer Res; 2007 Mar; 67(6):2729-35. PubMed ID: 17363594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Placental growth factor upregulation is a host response to antiangiogenic therapy.
    Bagley RG; Ren Y; Weber W; Yao M; Kurtzberg L; Pinckney J; Bangari D; Nguyen C; Brondyk W; Kaplan J; Teicher BA
    Clin Cancer Res; 2011 Mar; 17(5):976-88. PubMed ID: 21343374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3D modeling of effects of increased oxygenation and activity concentration in tumors treated with radionuclides and antiangiogenic drugs.
    Lagerlöf JH; Kindblom J; Bernhardt P
    Med Phys; 2011 Aug; 38(8):4888-93. PubMed ID: 21928660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
    Epstein RJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
    Sini P; Wyder L; Schnell C; O'Reilly T; Littlewood A; Brandt R; Hynes NE; Wood J
    Clin Cancer Res; 2005 Jun; 11(12):4521-32. PubMed ID: 15958638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.
    Kim ES; Serur A; Huang J; Manley CA; McCrudden KW; Frischer JS; Soffer SZ; Ring L; New T; Zabski S; Rudge JS; Holash J; Yancopoulos GD; Kandel JJ; Yamashiro DJ
    Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11399-404. PubMed ID: 12177446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
    Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
    Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
    Limaverde-Sousa G; Sternberg C; Ferreira CG
    Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Vascular endothelial growth factor (VEGF) in endocrinology and oncology].
    Kajdaniuk D; Marek B; Fołtyn W; Kos-Kudła B
    Endokrynol Pol; 2011; 62 Suppl 3():14-22. PubMed ID: 22161982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
    Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
    Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
    Kienast Y; Klein C; Scheuer W; Raemsch R; Lorenzon E; Bernicke D; Herting F; Yu S; The HH; Martarello L; Gassner C; Stubenrauch KG; Munro K; Augustin HG; Thomas M
    Clin Cancer Res; 2013 Dec; 19(24):6730-40. PubMed ID: 24097868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy.
    Bagri A; Berry L; Gunter B; Singh M; Kasman I; Damico LA; Xiang H; Schmidt M; Fuh G; Hollister B; Rosen O; Plowman GD
    Clin Cancer Res; 2010 Aug; 16(15):3887-900. PubMed ID: 20554752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
    Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
    J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasculatures in tumors growing from preirradiated tissues: formed by vasculogenesis and resistant to radiation and antiangiogenic therapy.
    Chen FH; Chiang CS; Wang CC; Fu SY; Tsai CS; Jung SM; Wen CJ; Lee CC; Hong JH
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1512-21. PubMed ID: 21621344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.